CD274 and neoplasm: In previous studies, several predictive biomarkers for successful immunotherapy including tumor mutational burden (TMB) (3, 4), gene expression profile (5), PD-L1 expression (6), tumor-infiltrating lymphocytes (7), and high microsatellite instability (8) have been reported.